<story><title>The antimicrobial resistance crisis needs action now</title><url>https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001918</url></story><parent_chain></parent_chain><comment><author>lofatdairy</author><text>BTW for anyone who wants to help but thinks this is mostly wetlab&amp;#x2F;drug development work. There&amp;#x27;s quite a bit of room in the space for the computer-vision side of things to improve decision-making and time to treat. I think it&amp;#x27;s mostly based on phenotyping by imaging and identifying low-specimen cultures but I might be totally wrong.&lt;p&gt;Some competitions:&lt;p&gt;- &lt;a href=&quot;https:&amp;#x2F;&amp;#x2F;longitudeprize.org&amp;#x2F;&quot; rel=&quot;nofollow&quot;&gt;https:&amp;#x2F;&amp;#x2F;longitudeprize.org&amp;#x2F;&lt;/a&gt;&lt;p&gt;- &lt;a href=&quot;https:&amp;#x2F;&amp;#x2F;dpcpsi.nih.gov&amp;#x2F;AMRChallenge&amp;#x2F;Finalists&quot; rel=&quot;nofollow&quot;&gt;https:&amp;#x2F;&amp;#x2F;dpcpsi.nih.gov&amp;#x2F;AMRChallenge&amp;#x2F;Finalists&lt;/a&gt;&lt;p&gt;Some previous work using various ML piplines:&lt;p&gt;- &lt;a href=&quot;https:&amp;#x2F;&amp;#x2F;phastdiagnostics.com&amp;#x2F;&quot; rel=&quot;nofollow&quot;&gt;https:&amp;#x2F;&amp;#x2F;phastdiagnostics.com&amp;#x2F;&lt;/a&gt;&lt;p&gt;- &lt;a href=&quot;https:&amp;#x2F;&amp;#x2F;acceleratediagnostics.com&amp;#x2F;publications&amp;#x2F;&quot; rel=&quot;nofollow&quot;&gt;https:&amp;#x2F;&amp;#x2F;acceleratediagnostics.com&amp;#x2F;publications&amp;#x2F;&lt;/a&gt;&lt;p&gt;- &lt;a href=&quot;https:&amp;#x2F;&amp;#x2F;talisbio.com&amp;#x2F;&quot; rel=&quot;nofollow&quot;&gt;https:&amp;#x2F;&amp;#x2F;talisbio.com&amp;#x2F;&lt;/a&gt;</text></comment>
<story><title>The antimicrobial resistance crisis needs action now</title><url>https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001918</url></story><parent_chain></parent_chain><comment><author>zosima</author><text>I am quite sure, that if a sufficient bounty was given out for developing new kinds of antimicrobials, they&amp;#x27;d be developed in no time.&lt;p&gt;The problem is that cost and risk of development and trials is too large for the current rewards, and hence there is very little new antimicrobials being developed. There are very many promising leads though, and either making development cheaper (by requiring smaller or fewer clinical trials) or ensuring good prices or bounties for successful development would likely create a plethora of antimicrobials in a quite short time frame.</text></comment>